EMD-79039

Single-particle
3.6 Å
EMD-79039
3D View Gallery
Deposition: 11/09/2026
Map released: 30/09/2026
Last modified: 30/09/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-79039

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-38pm summary report (pdf.gz) Map-38pm FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Australian bat lyssavirus glycoprotein PH domain in complex with broadly neutralizing human antibodies A6 and RVC20

EMD-79039

Single-particle
3.6 Å
EMD-79039
3D View Gallery
Deposition: 11/09/2026
Map released: 30/09/2026
Last modified: 30/09/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens, Lyssavirus australis
Sample: Lyssavirus australis
Fitted models: 38pm

Deposition Authors: Xu K, Xu Y
Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection.
Huaman C, Xu Y, Lott NM, Santorella EM, Rader M, Strazzella AM, Clouse C, King JM, Melnyk M, Hong J, Yan L, Paskey AC, Luquette AE, Malagon F, Cer RZ, Bishop-Lilly KA, Perl DP, Broder CC, Xu K, Schaefer BC
(2026) Emerg Microbes Infect , 2736987 - 2736987
PUBMED: 42758862
DOI: doi:10.1080/22221751.2026.2736987
ISSN: 2222-1751